Results 1 to 10 of about 6,034 (173)

Maraviroc attenuates orbital remodeling, inflammation, and lipid dysregulation in a murine model of thyroid eye disease associated with Graves’ disease [PDF]

Frontiers in Endocrinology
BackgroundGraves’ disease (GD) is an autoimmune condition that can extend beyond the thyroid, leading to thyroid eye disease (TED), a disorder marked by orbital inflammation and tissue remodeling.MethodsWe explored the therapeutic potential of maraviroc,
Fahimeh Hashemi Arani, Anne Gulbins, Mareike Horstmann, Insa Nolte, Anke Daser, Nikolaos E. Bechrakis, J Paul Banga, Erich Gulbins, Anja Eckstein, Gina-Eva Görtz   +9 more
doaj   +2 more sources

Preclinical systematic review of CCR5 antagonists as cerebroprotective and stroke recovery enhancing agents [PDF]

eLife
C-C chemokine receptor type 5 (CCR5) antagonists may improve both acute stroke outcome and long-term recovery. Despite their evaluation in ongoing clinical trials, gaps remain in the evidence supporting their use.
Ayni Sharif, Matthew S Jeffers, Dean A Fergusson, Raj Bapuji, Stuart G Nicholls, John Humphrey, Warren Johnston, Ed Mitchell, Mary-Ann Speirs, Laura Stronghill, Michele Vuckovic, Susan Wulf, Risa Shorr, Dar Dowlatshahi, Dale Corbett, Manoj M Lalu   +15 more
doaj   +2 more sources

Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants

HIV Research & Clinical Practice, 2022
Background Fostemsavir is an oral prodrug of temsavir, a first‐in‐class attachment inhibitor that binds HIV‐1 gp120, preventing initial HIV attachment and entry into host immune cells.
Mary Beth Wire, Mindy Magee, Peter Ackerman, Cyril Llamoso, Katy Moore   +4 more
doaj   +1 more source

Effects of maraviroc and efavirenz on markers of immune activation and inflammation and associations with CD4+ cell rises in HIV-infected patients. [PDF]

PLoS ONE, 2010
Maraviroc treatment for HIV-1 infected patients results in larger CD4(+) T cell rises than are attributable to its antiviral activity alone. We investigated whether this is due to modulation of T cell activation and inflammation.Thirty maraviroc-treated ...
Nicholas Funderburg, Magdalena Kalinowska, James Eason, James Goodrich, Jayvant Heera, Howard Mayer, Natasa Rajicic, Hernan Valdez, Michael M Lederman   +8 more
doaj   +1 more source

HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc. [PDF]

PLoS ONE, 2015
Maraviroc is an HIV entry inhibitor that alters the conformation of CCR5 and is poorly efficient in patients infected by viruses that use CXCR4 as an entry coreceptor.
Christophe Rodriguez, Cathia Soulié, Anne-Geneviève Marcelin, Vincent Calvez, Diane Descamps, Charlotte Charpentier, Philippe Flandre, Patricia Recordon-Pinson, Pantxika Bellecave, Jean-Michel Pawlotsky, Bernard Masquelier, ANRS AC11 Study Group   +11 more
doaj   +1 more source

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice

Pharmaceuticals, 2021
Influenza A virus (IAV) infection is a common cause of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). Since macrophage inflammatory protein 1 α, a chemokine that acts through CC-chemokine receptor (CCR)-5, appears elevated in COPD
Maximiliano Ruben Ferrero, Cristiana Couto Garcia, Marcella Dutra de Almeida, Jullian Torres Braz da Silva, Daniella Bianchi Reis Insuela, Tatiana Paula Teixeira Ferreira, Diego de Sá Coutinho, Carolina Trindade de Azevedo, Patrícia Machado Rodrigues e Silva, Marco Aurélio Martins   +9 more
doaj   +1 more source

Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial. [PDF]

PLoS ONE, 2015
The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore,
Steven F L van Lelyveld, Julia Drylewicz, Maaike Krikke, Ellen M Veel, Sigrid A Otto, Clemens Richter, Robin Soetekouw, Jan M Prins, Kees Brinkman, Jan Willem Mulder, Frank Kroon, Ananja Middel, Jori Symons, Jori Symons, Annemarie M J Wensing, Monique Nijhuis, José A M Borghans, Kiki Tesselaar, Andy I M Hoepelman, MIRS study group   +19 more
doaj   +1 more source

Tropism prediction in HIV-1 variants circulating in Cuba, 2017-2019: Implications for the pathogenesis of infection and response to Maraviroc

Journal of Microbiology and Infectious Diseases, 2023
Background: Tropism is determined by the ability of HIV-1 to bind to the receptors CCR5 or CXCR4 to enter the target cell, which has implications for the pathogenesis of the disease and affects treatment options.
Anamary Suarez Batista, Lissette Perez Santos, Liuber Yans Machado Zaldívar, Melissa Mendez Gonzalez, Yanet Pintos Saavedra, Jorge Perez Ávila, Hector Manuel Díaz Torres, Tamara Rojas Nuñez, Juliet María Enriquez Puertas, Yoanna Baños Morales, Enrique Noa Romero, Vivian Kourí Cardella   +11 more
doaj   +1 more source

Case series: Maraviroc and pravastatin as a therapeutic option to treat long COVID/Post-acute sequelae of COVID (PASC)

Frontiers in Medicine, 2023
Post-acute sequelae of COVID (PASC), or long COVID, is a multisystem complication of SARS-CoV-2 infection that continues to debilitate millions worldwide thus highlighting the public health importance of identifying effective therapeutics to alleviate ...
Bruce K. Patterson, Ram Yogendra, Jose Guevara-Coto, Rodrigo A. Mora-Rodriguez, Eric Osgood, John Bream, Purvi Parikh, Mark Kreimer, Devon Jeffers, Cedric Rutland, Gary Kaplan, Michael Zgoda   +11 more
doaj   +1 more source

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey.

PLoS ONE, 2019
ObjectivesThe study aimed to survey maraviroc use and assess effectiveness and durability of maraviroc-containing antiretroviral treatment (ART) in routine practice across Europe.MethodsData were retrieved from 26 cohorts in 8 countries comprising adults
Andrea De Luca, Patrizio Pezzotti, Charles Boucher, Matthias Döring, Francesca Incardona, Rolf Kaiser, Thomas Lengauer, Nico Pfeifer, Eugen Schülter, Anne-Mieke Vandamme, Maurizio Zazzi, Anna Maria Geretti, EucoHIV Study Group   +12 more
doaj   +1 more source